Investigational drug plus chemotherapy for advanced colorectal cancer
Part of Brain & nervous system, Cancer, Digestive system, Genetic & congenital clinical trials.
This trial is for people with advanced colorectal cancer that has stopped responding to first-line treatment. It tests a combination of chemotherapy, a targeted therapy, and an investigational drug to see if it can help slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of colorectal cancer called metastatic colorectal adenocarcinoma with a specific genetic status called pMMR/MSS.
- You must be 18 years or older.
- You must have already tried one type of chemotherapy that included oxaliplatin, and it either caused bad side effects or stopped working.
- You must be well enough to carry out daily activities with little or no help (ECOG status 0-2).
- You must not have had prior treatment with irinotecan (a chemotherapy drug) or with certain immunotherapies (PD-1 or CTLA-4 inhibitors).
- You must not have serious other medical conditions like uncontrolled infections, heart problems, or active autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
This trial tests adding a new immunotherapy drug (QL1706) to standard chemotherapy plus bevacizumab for people with colorectal cancer that has spread and hasn't been treated yet. It aims to see if the combination works better than standard treatment alone.
This trial tests a new drug combination (QL1706 and bevacizumab) for people with advanced colorectal cancer that has a specific genetic feature (MSI-H/dMMR). It aims to see if this treatment can help shrink or control the cancer.
This trial tests a different way of giving a chemotherapy drug called irinotecan, along with two other drugs (5-FU and bevacizumab), for people whose cancer got worse after first-line treatment. It aims to see if this combination can help control the cancer.
This trial tests a new drug combined with a standard treatment for advanced colorectal cancer that has not responded to earlier therapies. It aims to see if the combination can help slow the cancer's growth.
This trial tests new treatment combinations for colorectal cancer that has spread (metastatic). It is for people whose cancer is mismatch repair proficient (pMMR) or microsatellite stable (MSS) and who have not had previous treatment for metastatic disease.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.